QualityStocks would like to highlight Bacterin International Holdings, Inc. (NYSE: BONE). The company develops, manufactures, and markets biologics products in the United States and internationally. The company's products are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, and cartilage regeneration in knee and other joint surgeries.
In the company’s news yesterday,
Bacterin International Holdings announced that the first clinical results using the OsteoSponge SC product for regeneration of subchondral bone in complex lesions of the talus involving advanced subchondral bone damage have been published in the peer-reviewed journal, Foot & Ankle Specialist. The article reported on six month, post-operative outcomes on 7 patients which included pain and activity scales as well as radiographic findings. In each case, the patients reported a clinically significant reduction in pain and improvement in activity over the six month period. MRIs confirmed graft incorporation and restoration of an intact subchondral plate.
In addition, the company has begun a 75 patient registration for OsteoSponge SC, with the first patient enrolled in July, and has received approval to proceed in five of six sites so far. To date, OsteoSponge SC has been implanted in more than 250 patients and continues to produce excellent clinical results.
Bacterin estimates the current size of the market addressing subchondral defects in the foot, ankle, and knee to be approximately $1.7 billion annually. The market is expected to grow in future years as more advanced repair technologies become available. The company also believes that its OsteoSponge SC product may significantly change the standard of care globally for the treatment of damaged subchondral bone.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
